Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome
Tibor Kempf, Kai C Wollert, Tibor Kempf, Kai C Wollert
Abstract
Patients with adult respiratory distress syndrome (ARDS) are highly heterogeneous but current therapies are rather uniform and largely supportive. In the previous issue of Critical Care, Clark and colleagues report that the biomarker GDF-15 provides prognostic information in ARDS that is additive to that provided by the APACHE III score. Patients with high levels of growth-differentiation factor 15 (GDF-15) had a higher mortality and more complicated hospital course. Biomarkers such as GDF-15 may help us to identify patients at higher risk who may eventually benefit from more personalized and targeted therapies.
References
- Clark BJ, Bull TM, Benson AB, Stream AR, Macht M, Gaydos J, Meadows C, Burnham EL, Moss M. Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study. Crit Care. 2013;17:R92. doi: 10.1186/cc12737.
- Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;17:473–481. doi: 10.1093/aje/kws207.
- Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;17:962–971. doi: 10.1161/CIRCULATIONAHA.106.650846.
- Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;17:1018–1025. doi: 10.1164/rccm.200712-1786OC.
- Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, Ma YT, Deb M, Tountopoulou A, Lambrecht J, Heeren M, Lichtinghagen R, Wollert KC, Weissenborn K. Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. Cerebrovasc Dis. 2011;17:72–78. doi: 10.1159/000328233.
- Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;17:534–541. doi: 10.1164/rccm.200802-235OC.
- Kempf T, Sinning JM, Quint A, Bickel C, Sinning C, Wild PS, Schnabel R, Lubos E, Rupprecht HJ, Münzel T, Drexler H, Blankenberg S, Wollert KC. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet. 2009;17:286–292. doi: 10.1161/CIRCGENETICS.108.824870.
- Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;17:1387–1395. doi: 10.1161/CIRCULATIONAHA.109.928846.
- Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, van der Weide P, Klöpping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;17:1249–1256. doi: 10.1093/eurjhf/hfs120.
Source: PubMed